Identification of a new class of PAX3-FKHR target promoters: A role of the Pax3 paired box DNA binding domain

Oncogene

Volumn 26, Issue 11, 2007, Pages 1595-1605

  Zhang, L ^a   Wang, C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chromosomal translocation; Oncogene; Rhabdomyosarcoma; Transcription

Indexed keywords

MYOGENIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ARTICLE; BINDING SITE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MUSCLE CANCER; MYOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RHABDOMYOSARCOMA;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FORKHEAD TRANSCRIPTION FACTORS; HELA CELLS; HUMANS; MICE; MYOGENIN; NIH 3T3 CELLS; PAIRED BOX TRANSCRIPTION FACTORS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC;

EID: 33947158748     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209958     Document Type: Article

References (39)

1. Anderson J, Ramsay A, Gould S, Pritchard-Jones K. (2001). Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Am J Path 159: 1089-1096.
2. Barr FG. (1997). Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma. Curr Topics Micro Immun 220: 113-129.
3. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. (1993). Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 3: 113-117.
4. Begum S, Emani N, Cheung A, Wilkins O, Der S, Hamel PA. (2005). Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 24: 1860-1872.
5. Bernasconi M, Remppis A, Fredericks WJ, Rauscher III FJ, Schafer BW. (1996). Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 93: 13164-13169.
6. Buchberger A, Ragge K, Arnold HH. (1994). The myogenin gene is activated during myocyte differentiation by pre-existing, not newly synthesized transcription factor MEF-2. J Biol Chem 269: 17289-17296.
7. Cao Y, Wang C. (2000). The COOH-terminal transactivation domain plays a key role in regulating the in vitro and in vivo function of Pax3 homeodomain. J Biol Chem 275: 9854-9862.
8. Chalepakis G, Goulding M, Read A, Strachan R, Gruss P. (1994a). Moleulcar basis of splotch and Waardenburg Pax-3 mutations. Proc Natl Acad Sci USA 91: 3685-3689.
9. Chalepakis G, Jones FS, Eelman GM, Gruss P. (1994b). Pax-3 contains domains for transcription activation and transcription inhibition. Proc Natl Acad Sci USA 91: 12745-12749.
10. Chalepakis G, Gruss P. (1995). Identification of DNA recognition sequences for the Pax3 paired domain. Gene 162: 267-270.
11. Cheng TC, Hanley TA, Mudd J, Merlie JP, Olson EN. (1992). Mapping of myogenin transcription during embryogenesis using transgenes linked to the myogenin control region. J Cell Biol 119: 1649-1656.
12. Cheng TC, Wallace MC, Merlie JP, Olson E.N. (1993). Separable regulatory elements governing myogenin transcription in mouse embryogenesis. Science 261: 215-218.
13. De Pitta C, Tombolan L, Albiero G, Sartori F, Romualdi C, Jurman G et al. (2006). Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 118: 2772-2781.
14. Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S et al. (2000). Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Path 156: 399-408.
15. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ et al. (1987). A specific abnormality in rhabdomyosarcoma. Cyto Cell Genet 45: 148-155.
16. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN. (1995). Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270: 11719-11722.
17. Epstein JA, Song B, Lakkis M, Wang C. (1998). Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 18: 4118-4130.
18. Folpe AL. (2002). MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Path 9: 198-203.
19. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG et al. (1995). The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15: 1522-1535.
20. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. (1991). Pax3, a novel murine DNA binding proein expressed duringearly neurogeneisis. EMBO J 10: 1135-1147.
21. Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D et al. (2004). Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101: 2817-2824.
22. Jen Y, Weintraub H, Benezra R. (1992). Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev 6: 1466-1479.
23. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. (2004a). Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18: 2614-2626.
24. Keller C, Hansen MS, Coffin CM, Capecchi MR. (2004b). Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18: 2608-2613.
25. Khan J, Bittner ML, Sall LH, Teichmann U, Azorsa DO, Gooden GC et al. (1999). cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96: 13264-13269.
26. Lam PYP, Sublett JE, Hollenbach AD, Roussel MF. (1999). The oncogenic potential of the PAX3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-Box DNA binding domain. Mol Cell Biol 19: 594-601.
27. Malik S, Huang CF, Schmidt J. (1995). The role of the CANNTG promoter element (E box) and the myocyte-enhancer-binding-factor-2 (MEF-2) site in the transcriptional regulation of the chick myogenin gene. Eur J Biochem 230: 88-96.
28. Michelagnoli MP, Burchill S.A, Cullinane C, Selby PJ, Lewis IJ. (2003). Myogenin-a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1. Med Pediatr Oncol 40: 1-8.
29. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J et al. (2000). Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 14: 574-584.
30. Scheidler S, Fredericks WJ, Rauscher JF, Barr GF, Vogt PK. (1996). The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 93: 9805-9809.
31. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. (1993). Fusion of PAX3 to a member of the Forkhead family of transcripton factors in human alveolar rhabdomyosarcoma. Cancer Res 53: 5108-5112.
32. Spicer DB, Rhee J, Cheung WL, Lassar AB. (1996). Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 272: 1476-1480.
33. Spitz F, Demignon J, Porteu A, Kahn A, Concordet JP, Daegelen D et al. (1998). Expression of myogenin during embryogenesis is controlled by Six/sine oculis homeoproteins through a conserved MEF3 binding site. Proc Natl Acad Sci USA 95: 14220-14225.
34. Tapscott SJ, Thayer MJ, Weintraub H. (1993). Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259: 1450-1453.
35. Turc-Carel C, Lizard-Nacol S, Justrabo E, Favrot M, Tabone E. (1986). Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cyotgeneti 19: 361-362.
36. Wang-Wuu S, Soukup S, Ballard E, Gotwals B, Lampkin B. (1988). Chromosomal analysis of sixteen human rhabdomyosarcoma. Cancer Res 48: 983-987.
37. Weintraub M, Kalebic T, Helman JL, Bhatia GK. (1997). Disruption of the MyoD/p21 pathway in rhabdomyosarcoma. Sarcoma 1: 135-141.
38. Yee SP, Rigby PW. (1993). The regulation of myogenin gene expression during the embryonic development of the mouse. Genes Dev 7: 1277-1289.
39. Zhang L, Wang C. (2006). F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 25: 2615-2627.